Christopher Moxham is CSO at Fulcrum Therapeutics, Inc. (FULC). They have made 1 open-market trade across 1 company since 2021, most recently 2021-08-10.
CIK 0001843784
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| FULC | 20,714 | $76K |
Shares reported on the most recent Form 4, priced at the 2021-08-12 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| FULC | SELL | 2021-08-10 | 2021-08-12 | $17.60 | $911K | +22.0% | +22.0% | -11.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.